9 research outputs found
Friction force on a vortex due to the scattering of superfluid excitations in helium II
The longitudinal friction acting on a vortex line in superfluid He is
investigated within a simple model based on the analogy between such vortex
dynamics and that of the quantal Brownian motion of a charged point particle in
a uniform magnetic field. The scattering of superfluid quasiparticle
excitations by the vortex stems from a translationally invariant interaction
potential which, expanded to first order in the vortex velocity operator, gives
rise to vortex transitions between nearest Landau levels. The corresponding
friction coefficient is shown to be, in the limit of elastic scattering
(vanishing cyclotron frequency), equivalent to that arising from the Iordanskii
formula. Proposing a simple functional form for the scattering amplitude, with
only one adjustable parameter whose value is set in order to get agreement to
the Iordanskii result for phonons, an excellent agreement is also found with
the values derived from experimental data up to temperatures about 1.5 K.
Finite values of the cyclotron frequency arising from recent theories are shown
to yield similar results. The incidence of vortex-induced quasiparticle
transitions on the friction process is estimated to be, in the roton dominated
regime, about 50 % of the value of the friction coefficient, 8 % of which
corresponds to roton-phonon transitions and 42 % to roton
ones.Comment: 15 pages, 4 figures; typos corrected, to be published in PR
Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: Results from five randomized controlled trials
Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial
Item does not contain fulltex
Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix
Phase II trial of weekly locoregional hyperthermia and cisplatin in patients with a previously irradiated recurrent carcinoma of the uterine cervix
Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial.
Contains fulltext :
69055.pdf (publisher's version ) (Closed access)PURPOSE: The local failure rate in patients with locoregionally advanced cervical cancer is 41-72% after radiotherapy (RT) alone, whereas local control is a prerequisite for cure. The Dutch Deep Hyperthermia Trial showed that combining RT with hyperthermia (HT) improved 3-year local control rates of 41-61%, as we reported earlier. In this study, we evaluate long-term results of the Dutch Deep Hyperthermia Trial after 12 years of follow-up. METHODS AND MATERIALS: From 1990 to 1996, a total of 114 women with locoregionally advanced cervical carcinoma were randomly assigned to RT or RT+HT. The RT was applied to a median total dose of 68 Gy. The HT was given once weekly. The primary end point was local control. Secondary end points were overall survival and late toxicity. RESULTS: At the 12-year follow-up, local control remained better in the RT+HT group (37% vs. 56%; p=0.01). Survival was persistently better after 12 years: 20% (RT) and 37% (RT+HT; p=0.03). World Health Organization (WHO) performance status was a significant prognostic factor for local control. The WHO performance status, International Federation of Gynaecology and Obstetrics (FIGO) stage, and tumor diameter were significant for survival. The benefit of HT remained significant after correction for these factors. European Organization for Research and Treatment of Cancer Grade 3 or higher radiation-induced late toxicities were similar in both groups. CONCLUSIONS: For locoregionally advanced cervical cancer, the addition of HT to RT resulted in long-term major improvement in local control and survival without increasing late toxicity. This combined treatment should be considered for patients who are unfit to receive chemotherapy. For other patients, the optimal treatment strategy is the subject of ongoing research